MarginsXMarginsX
Home › Markets › Health Care › ABCL

AbCellera Biologics Inc. Common Shares (ABCL)

ABCL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$11.12
-3.22% on the day
Market cap
$3.6B
Mid cap
Revenue · 2025
$75.1M
+160.6% on 2024
Net income · 2025
-$146.4M
-194.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/0001703057-26-000012-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerABCL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO year2020
SEC CIK0001703057
SEC industry codePharmaceutical Preparations
Incorporated inBC

Financials · 2025

LineValue
Revenue$75.1M
Net income-$146.4M
Operating income-$217.1M
Net margin-194.9%
Operating margin-289.0%
Revenue growth+160.6%
Cash$128.5M
Total assets$1.4B
P/E (computed)Net income was not positive
P/S (computed)48.3×

Warning signs

Cash runway
127.4 months
$163.8M cash at September 30, 2026
Share count, 1 year
+9.1%
2025-11-03 to 2026-11-04 · +12.6% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$2.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$163.8M cash; operating cash flow -$3.9M a quarter.Report 2026-09-30
Shares outstanding326,617,896 (2026-11-04); 299,335,048 a year earlier; 290,170,241 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-08-13
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Vancouver, Canada; changed auditors 1 time in 24 months8-K 4.01 2025-11-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $2.7M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$10.6M-$40.8M$26.9M$163.8MNo debt tags$67.9M10-Q 2026-11-09
Q2 2026
2026-06-30
$4.0M-$55.4M$25.9M$120.1MNo debt tags$66.2M10-Q 2026-08-05
Q1 2026
2026-03-31
$8.3M-$43.2M-$33.5M$77.1MNo debt tags$79.2M10-Q 2026-05-11
Q4 2025
2025-12-31
$44.9M-$8.9M-$34.7M$128.5MNo debt tags$75.1M10-K 2026-02-24
Q3 2025
2025-09-30
$9.0M-$57.1M-$52.6M$83.2MNo debt tags$35.3M10-Q 2026-11-09
Q2 2025
2025-06-30
$17.1M-$34.7M-$32.4M$92.4MNo debt tags$32.9M10-Q 2026-08-05
Q1 2025
2025-03-31
$4.2M-$45.6M-$11.6M$159.3MNo debt tags$23.1M10-Q 2026-05-11
Q4 2024
2024-12-31
$5.0M-$34.2M-$8.0M$156.3MNo debt tags$28.8M10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-13
Latest annual report10-K2026-02-24
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 329 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.3%
1 month-8.9%
3 months+4.7%
Year to date+236.0%
1 year+217.4%
From 52-week high-22.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OGNOrganon & Co. Common Stock$13.900.00%$3.7B
AMLXAmylyx Pharmaceuticals Inc.$27.80-8.22%$3.6B
PBLSParabilis Medicines Inc.$28.45+0.07%$3.5B
ELVNEnliven Therapeutics Inc.$47.62-2.42%$3.5B
IRONDisc Medicine Inc.$76.59-4.26%$3.5B
ARQTArcutis Biotherapeutics Inc.$27.15-3.93%$3.4B
XENEXenon Pharmaceuticals Inc. Common Shares$39.26-3.01%$3.9B
VKTXViking Therapeutics Inc.$26.80-8.28%$3.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier